Literature DB >> 10860842

Both amino- and carboxyl-terminal domains of TRAF3 negatively regulate NF-kappaB activation induced by OX40 signaling.

A Takaori-Kondo1, T Hori, K Fukunaga, R Morita, S Kawamata, T Uchiyama.   

Abstract

OX40 is a member of the tumor necrosis factor receptor (TNF-R) superfamily. We observed that overexpression of OX40 activated NF-kappaB, which was inhibited by dominant negative forms of TRAF2, NF-kappaB-inducing kinase (NIK), and IkappaB kinase (IKK) alpha. This indicates that OX40 signaling leads to NF-kappaB activation through the same cascade as TNF-R2. We then investigated the negative regulatory function of TRAF3 on OX40-induced NF-kappaB activation. TRAF3 blocked OX40-, TRAF2-induced NF-kappaB activation, but not NIK- and IKKalpha-induced NF-kappaB activation, indicating that TRAF3 blocks the pathway between TRAF2 and NIK. C-terminal deletion mutants as well as the N-terminal deletion mutant of TRAF3 inhibited NF-kappaB activation induced by OX40 or TRAF2. Since TRAF3 bound to OX40 through the C-terminal TRAF domain, the C-terminal domain is likely to work as a dominant negative mutant to compete the recruitment of TRAF2 to the receptor, which transmits the signal from OX40 to the downstream, NIK kinase. On the other hand, the N-terminal domain of TRAF3 seems to affect the downstream of TRAF2 binding. Thus, it is suggested that TRAF3 actively inhibits NF-kappaB activation induced by OX40. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10860842     DOI: 10.1006/bbrc.2000.2860

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation.

Authors:  Li-Fan Lu; Cory L Ahonen; Evan F Lind; Vanitha S Raman; W James Cook; Ling-Li Lin; Randolph J Noelle
Journal:  Blood       Date:  2007-03-14       Impact factor: 22.113

Review 2.  Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions.

Authors:  Joanne M Hildebrand; Zuoan Yi; Claire M Buchta; Jayakumar Poovassery; Laura L Stunz; Gail A Bishop
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

3.  NF-κB–inducing kinase plays an essential T cell–intrinsic role in graft-versus-host disease and lethal autoimmunity in mice.

Authors:  Susan E Murray; Fanny Polesso; Alexander M Rowe; Soumen Basak; Yoshinobu Koguchi; Katelynne Gardner Toren; Alexander Hoffmann; David C Parker
Journal:  J Clin Invest       Date:  2011-12       Impact factor: 14.808

Review 4.  Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions.

Authors:  Zuoan Yi; Wai Wai Lin; Laura L Stunz; Gail A Bishop
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-25       Impact factor: 7.638

5.  APOBEC3G targets specific virus species.

Authors:  Masayuki Kobayashi; Akifumi Takaori-Kondo; Keisuke Shindo; Aierken Abudu; Keiko Fukunaga; Takashi Uchiyama
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 6.  Role of CXCL1 in tumorigenesis of melanoma.

Authors:  Punita Dhawan; Ann Richmond
Journal:  J Leukoc Biol       Date:  2002-07       Impact factor: 4.962

Review 7.  The role of OX40-mediated co-stimulation in T-cell activation and survival.

Authors:  William L Redmond; Carl E Ruby; Andrew D Weinberg
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

Review 8.  The significance of OX40 and OX40L to T-cell biology and immune disease.

Authors:  Michael Croft; Takanori So; Wei Duan; Pejman Soroosh
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

9.  Role of NF kappa B activator Act1 in CD40-mediated signaling in epithelial cells.

Authors:  Youcun Qian; Zhendong Zhao; Zhengfan Jiang; Xiaoxia Li
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-27       Impact factor: 11.205

Review 10.  NF-kappaB activation in melanoma.

Authors:  Yukiko Ueda; Ann Richmond
Journal:  Pigment Cell Res       Date:  2006-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.